Literature DB >> 22444161

Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.

Carl Dahlöf1, Antoinette Maassen Van Den Brink.   

Abstract

The 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effective in migraine primarily by activating 5-HT(1B) , 5-HT(1D) , and 5-HT(1F) receptors. Ergotamine, dihydroergotamine, and methysergide, as well as the "triptan" sumatriptan, are all agonists for these receptors. The receptor profile and degree of selectivity of these four drugs differ, which is reflected by their side effects that limit their use in the acute and prophylactic treatment of migraine. The acute antimigraine efficacy of these remedies is very much dependent on the formulation used where, in general, parenteral formulations are more effective in reliving the symptoms of a migraine attack.
© 2012 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22444161     DOI: 10.1111/j.1526-4610.2012.02124.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  20 in total

1.  5-HT1D receptors inhibit the monosynaptic stretch reflex by modulating C-fiber activity.

Authors:  Ana M Lucas-Osma; Yaqing Li; Katie Murray; Shihao Lin; Sophie Black; Marilee J Stephens; Andrew H Ahn; C J Heckman; Keith K Fenrich; Karim Fouad; David J Bennett
Journal:  J Neurophysiol       Date:  2019-01-09       Impact factor: 2.714

Review 2.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 3.  Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.

Authors:  Stephen D Silberstein; Shashidhar H Kori
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

4.  DHE-Induced Peripheral Arterial Vasospasm in Primary Raynaud Phenomenon: Case Report.

Authors:  Jane Khalife; Clinton G Lauritsen; John Liang; Syed O Shah
Journal:  Neurohospitalist       Date:  2018-09-11

Review 5.  Ditans: a new prospective for the therapy of migraine attack?

Authors:  Giovanna Viticchi; Lorenzo Falsetti; Mauro Silvestrini; Marco Bartolini
Journal:  Neurol Sci       Date:  2022-07-11       Impact factor: 3.830

Review 6.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

7.  Effect of methysergide on pudendal inhibition of micturition reflex in cats.

Authors:  Yosuke Matsuta; Zeyad Schwen; Abhijith D Mally; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  Exp Neurol       Date:  2013-05-18       Impact factor: 5.330

8.  Advances in drug development for acute migraine.

Authors:  Ryan J Cady; Candace L Shade; Roger K Cady
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

9.  Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors.

Authors:  Abimael González-Hernández; Jair Lozano-Cuenca; Bruno A Marichal-Cancino; Antoinette MaassenVanDenBrink; Carlos M Villalón
Journal:  J Headache Pain       Date:  2018-05-25       Impact factor: 7.277

10.  Ergot Alkaloids (Re)generate New Leads as Antiparasitics.

Authors:  John D Chan; Prince N Agbedanu; Thomas Grab; Mostafa Zamanian; Peter I Dosa; Timothy A Day; Jonathan S Marchant
Journal:  PLoS Negl Trop Dis       Date:  2015-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.